New treatment targeting IL-17A for idiopathic pulmonary fibrosis
Official title: IL-17A mRNA-targeted oligonucleotide therapeutics in Idiopathic Pulmonary Fibrosis (IPF)
Funded at Targetsite Therapeutics Corporation · NIH-10761365 · Data updated 2026-11-12
This study is exploring a new treatment for idiopathic pulmonary fibrosis (IPF) that aims to reduce inflammation in the lungs, which could help improve lung function and quality of life for people living with this condition.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Targetsite Therapeutics Corporation NIH-funded |
| Lab location | 1 site (New Haven, United States) |
| Project start | August 18, 2023 |
| Project end | July 31, 2025 |
| Funding year | 2023 |
| Award (this year) | $245,000 |
| NIH project number | 1R43HL170910-01 |
| Project ID | NIH-10761365 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with idiopathic pulmonary fibrosis who are experiencing progressive symptoms.
✕Less likely to help
Patients with other forms of lung disease or those who do not have idiopathic pulmonary fibrosis may not benefit from this research.
What this research studies
This research investigates a novel therapeutic approach for idiopathic pulmonary fibrosis (IPF) by targeting the IL-17A mRNA with specific oligonucleotide agents. These agents are designed to block the production of inflammatory cytokines that contribute to the progression of IPF, a condition that severely impacts lung function and quality of life. The study will utilize a bleomycin-induced lung fibrosis model to assess the effectiveness of this treatment. Patients may benefit from a new, potentially more tolerable treatment option that addresses the underlying inflammation associated with IPF.
Why it matters
Potential benefit: If successful, this research could provide a new, effective treatment option for patients suffering from idiopathic pulmonary fibrosis.
How similar studies have gone: While targeting inflammatory pathways in IPF is a novel approach, similar strategies have shown promise in other inflammatory diseases, indicating potential for success.
Where this research is happening
-
Targetsite Therapeutics Corporation
New Haven, United States Active
Researchers
- Principal investigator: Ramgolam, Vinod Satisch — Targetsite Therapeutics Corporation
- Study coordinator: Ramgolam, Vinod Satisch
Related research
Other NIH-funded projects on the same topics.
-
Improving IPF care for Veterans with a new, practical care model
A project to help Veterans with idiopathic pulmonary fibrosis get timely, expert, and age-friendly care using a new care model.
-
New oral medicine targeting a pathway to treat idiopathic pulmonary fibrosis
This study is looking at a new pill that could help people with idiopathic pulmonary fibrosis (IPF) by targeting a specific pathway in the body, aiming to provide a safer and more effective treatment than what’s currently available.
-
Repurposing Pyrvinium as an Inhaled Therapy for Idiopathic Pulmonary Fibrosis
A patient-friendly look at a project trying to use an existing drug, pyrvinium, as an inhaled treatment option for idiopathic pulmonary fibrosis (IPF).
-
Screening new compounds to reverse gene signatures in IPF lungs
A researcher hopes to find compounds that reverse harmful gene changes in the lungs of people with idiopathic pulmonary fibrosis (IPF).
-
Unraveling IPF subtypes to guide prognosis and therapy
This grant aims to identify different IPF subtypes in the lung to improve how we predict outcomes and tailor treatments for people with IPF.
-
Novel antibody therapy to treat idiopathic pulmonary fibrosis
A small business gig is developing a targeted antibody drug (VSR-H5) to treat idiopathic pulmonary fibrosis in patients, aiming for better safety and effectiveness than current medicines.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.